faster aspart Fiasp
Selected indexed studies
- [Faster aspart insulin (FIASP®)]. (Rev Med Liege, 2018) [PMID:29676875]
- [Pharmacological and clinical characteristics of Insulin Faster Aspart (Fiasp®)]. (Medicina (B Aires), 2022) [PMID:36220033]
- Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus. (Clin Pharmacokinet, 2019) [PMID:29978361]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus. (2019) pubmed
- [Faster aspart insulin (FIASP®)]. (2018) pubmed
- [Pharmacological and clinical characteristics of Insulin Faster Aspart (Fiasp®)]. (2022) pubmed
- Efficacy and safety of faster aspart in insulin pumps in children and adolescents with type 1 diabetes mellitus: A single-center study with real-world data. (2023) pubmed
- [Faster Insulin Aspart - a new prandial insulin analogue]. (2017) pubmed
- Hybrid Closed-Loop with Faster Insulin Aspart Compared with Standard Insulin Aspart in Very Young Children with Type 1 Diabetes: A Double-Blind, Multicenter, Randomized, Crossover Study. (2023) pubmed
- Faster-acting insulin aspart versus insulin aspart for adults with type 1 diabetes treated with non-automated insulin pump and continuous glucose monitoring-A double-blind randomized controlled crossover trial. (2025) pubmed
- Pump Users Clamor for Faster Insulin: Is Fast-Acting Insulin Aspart Ready for Them? (2018) pubmed
- Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study. (2021) pubmed
- CopenFast trial: Faster-acting insulin Fiasp versus insulin NovoRapid in the treatment of women with type 1 or type 2 diabetes during pregnancy and lactation - a randomised controlled trial. (2021) pubmed